ARTICLE | Product Development
U.K.’s ACCORD platform trial to feed therapies into COVID-19 master protocols
BioCentury is providing this story for free given the urgent need for information about the COVID-19 crisis. For more analysis, sign up for our daily email.
April 30, 2020 5:04 PM UTC
Updated on Apr 30, 2020 at 10:10 PM UTC
The U.K. has launched the ACCORD platform trial to quickly test potential COVID-19 treatments that could be fast-tracked into larger master protocol trials.
The Accelerating COVID-19 Research & Development platform (ACCORD) study is a nationwide Phase II trial that is meant to rapidly assess new treatments for early signs of efficacy in treating COVID-19. If successful, the therapies would progress into one of three existing COVID-19 master protocol trials in the U.K.: the RECOVERY, PRINCIPLE and REMAP-CAP studies...
BCIQ Company Profiles